Atrial fibrillation risk by age in patients with chronic lymphocytic leukemia treated with covalent Bruton tyrosine kinase inhibitors

ASH 2026 • CLL/SLL • Zanubrutinib • Poster

Daniel Ermann, MD

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

This retrospective analysis of the US Symphony database evaluated one-year atrial fibrillation (AFib) rates by age among adults aged 55 to 79 years with chronic lymphocytic leukemia (CLL) and assessed AFib risk across 2-year age groups among patients who received first-line (1L) covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy. A total of 213,473 CLL patients aged 55-79 years were identified; the mean Charlson Comorbidity Index (CCI) score was 3.1, and 43.2% had hypertensive disease. The 1-year AFib rate in the overall CLL population increased linearly with age, from 3.5% at age 55, to 13.6% at age 70, and 24.7% at age 79. In the sensitivity analysis excluding patients with pre-existing AFib, the 1-year rate of new-onset AFib increased progressively from 1.9% at age 59, to 5.5% at age 70, and 8.6% at age 79. Among 1L cBTKi patients, ibrutinib was received by 14,243 patients, acalabrutinib by 5,105, and zanubrutinib by 1,777; mean CCI scores were 3.3 for zanubrutinib, 3.3 for acalabrutinib, and 2.8 for ibrutinib. AFib rates at ages 55-56, 69-70, and 79 were 5.1%, 16.6%, and 22.8% with ibrutinib; 4.4%, 12.3%, and 18.6% with acalabrutinib; and 0%, 9.5%, and 16.0% with zanubrutinib, respectively. Overall, AFib rates by 2-year age group with 1L zanubrutinib were consistently lower than those observed with 1L ibrutinib and 1L acalabrutinib.

Population Intervention / Exposure Comparator Outcomes
Adults aged 55 to 79 years with chronic lymphocytic leukemia in the US Symphony database. Zanubrutinib Acalabrutinib or ibrutinib One-year atrial fibrillation rates by single-year or 2-year age group, and new-onset atrial fibrillation after excluding patients with baseline atrial fibrillation.

FAQs

This study evaluated one-year atrial fibrillation (AFib) rates by age among patients with chronic lymphocytic leukemia (CLL) in the US Symphony database and assessed AFib risk across 2-year age groups among patients who received first-line covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy.

This was a retrospective analysis of the US Symphony database. Adult CLL patients aged 55 to 79 years were identified; the exact age of patients aged ≥80 years could not be determined due to privacy protections. One-year AFib rates were assessed by single year of age among the overall CLL population. A further exploratory analysis was conducted among patients who received first-line cBTKi, summarizing 1-year AFib rates across 2-year age groups. A second descriptive analysis excluded patients with pre-existing AFib at baseline, defined as an AFib diagnosis occurring in the 1 year on or before the index date. No adjusted head-to-head comparisons between cBTKi treatments were performed.

A total of 213,473 CLL patients aged 55-79 years were identified. The mean Charlson Comorbidity Index (CCI) score was 3.1. Key comorbidities included hypertensive disease (43.2%), heart disease (21.1%), diabetes mellitus (19.3%), kidney disease (13.9%), other cancers (13.5%), COPD (8.0%), cerebrovascular disease (6.0%), liver disease (4.6%), and peripheral vascular disease (3.9%).

The 1-year rate of AFib increased linearly with age, from 3.5% at age 55 to 13.6% at age 70 and 24.7% at age 79. In the sensitivity analysis excluding patients with pre-existing AFib, the 1-year rate of new-onset AFib increased progressively from 1.9% at age 59 to 5.5% at age 70 and 8.6% at age 79.

Among patients who initiated first-line cBTKi therapy, 14,243 received ibrutinib, 5,105 received acalabrutinib, and 1,777 received zanubrutinib. Mean CCI scores were 3.3 with zanubrutinib, 3.3 with acalabrutinib, and 2.8 with ibrutinib; rates of heart disease, hypertensive disease, diabetes, and kidney disease were numerically higher in the zanubrutinib and acalabrutinib cohorts. Among patients who received 1L ibrutinib, AFib rates were 5.1% at ages 55-56, 16.6% at ages 69-70, and 22.8% at age 79. Corresponding rates for 1L acalabrutinib were 4.4%, 12.3%, and 18.6%, respectively, and for 1L zanubrutinib were 0%, 9.5%, and 16.0%, respectively. Overall, AFib rates by 2-year age group with 1L zanubrutinib were consistently lower than those observed with 1L ibrutinib and 1L acalabrutinib across all age strata. Among patients without baseline AFib (ibrutinib: n=13,050; acalabrutinib: n=4,535; zanubrutinib: n=1,579), new-onset AFib rates followed similar patterns but were uniformly lower, ranging from 3.8%-15.5%, 0.8%-10.3%, and 0%-7.0%, respectively.

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed